BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment.
BIOMIMESYS®Liver scaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver-ECM composition.

 


gregory

gregory

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

Innovation for hepatotoxicity in vitro research models | HCS Pharma · July 16, 2019 at 1:49 pm

[…] better mimic the cell microenvironment, we have developed in vitro tests in different models and thanks to our technology for 3D cell culture BIOMIMESYS® Liver hydroscaffold we can model the […]

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: